The present disclosure relates to a pharmaceutical composition containing a poloxamer, a stabilization polymer, and Lactobacillus, as well as methods of making and using, and kits containing the composition.
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Dietary supplements; Vitamins; Probiotic preparations; Vaginal preparations and suppositories for balancing vaginal microbiome, restoring vaginal pH, support vaginal immune response, and enhance vaginal health
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Dietary supplements; Vitamins; Probiotic preparations; Vaginal preparations and suppositories for balancing vaginal microbiome, restoring vaginal pH, support vaginal immune response, and enhance vaginal health
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Pharmaceutical preparations; Pharmaceutical preparations for treating dysmenorrhea, pelvic pain, sexual pain, endometriosis and symptoms of menopause affecting sex; Analgesics; Vaginal preparations and suppositories for treatment of pain, release of selective estrogen receptor modulators, and vaginal melatonin; Intravaginal drug delivery device for the continuous release of hormones; Hormones; Hormone replacement therapy preparations
05 - Produits pharmaceutiques, vétérinaires et hygièniques
10 - Appareils et instruments médicaux
42 - Services scientifiques, technologiques et industriels, recherche et conception
Produits et services
Pharmaceutical preparations; Pharmaceutical preparations for use in the fields of women’s health, reproductive health, and sexual health; Vaginal preparations and suppositories for use in the fields of women’s health, reproductive health, and sexual health; Pharmaceutical preparations for preventing, treating, managing diseases, disorders, and conditions affecting the vagina; Analgesics; Anti-infectives; Hormones; Hormone replacement therapy preparations; Vaginal preparations; Vaginal suppositories; Vaginal supplements; Medicated topical creams; Dietary supplements; Vitamins; Probiotics; Drug delivery agents; Drug delivery devices; Contraceptive preparations Medical apparatus for use in women’s health; Contraceptive apparatus Research and development of medical preparations, medical products, and medical devices in the field of women’s health, reproductive health, and sexual health; Providing medical scientific research information in the fields of women’s health, reproductive health, and sexual health
05 - Produits pharmaceutiques, vétérinaires et hygièniques
10 - Appareils et instruments médicaux
42 - Services scientifiques, technologiques et industriels, recherche et conception
Produits et services
Pharmaceutical preparations; Pharmaceutical preparations for use in the fields of women’s health, reproductive health, and sexual health; Vaginal preparations and suppositories for use in the fields of women’s health, reproductive health, and sexual health; Pharmaceutical preparations for preventing, treating, managing diseases, disorders, and conditions affecting the vagina; Analgesics; Anti-infectives; Hormones; Hormone replacement therapy preparations; Vaginal preparations; Vaginal suppositories; Vaginal supplements; Medicated topical creams; Dietary supplements; Vitamins; Probiotics; Drug delivery agents; Drug delivery devices; Contraceptive preparations Medical apparatus for use in women’s health; Contraceptive apparatus Research and development of medical preparations, medical products, and medical devices in the field of women’s health, reproductive health, and sexual health; Providing medical scientific research information in the fields of women’s health, reproductive health, and sexual health
05 - Produits pharmaceutiques, vétérinaires et hygièniques
10 - Appareils et instruments médicaux
42 - Services scientifiques, technologiques et industriels, recherche et conception
Produits et services
Pharmaceutical preparations; Pharmaceutical preparations for use in the fields of women’s health, reproductive health, and sexual health; Vaginal preparations and suppositories for use in the fields of women’s health, reproductive health, and sexual health; Pharmaceutical preparations for preventing, treating, managing diseases, disorders, and conditions affecting the vagina; Analgesics; Anti-infectives; Hormones; Hormone replacement therapy preparations; Vaginal preparations; Vaginal suppositories; Vaginal supplements; Medicated topical creams; Dietary supplements; Vitamins; Probiotics; Drug delivery agents; Drug delivery devices; Contraceptive preparations Medical apparatus for use in women’s health; Contraceptive apparatus Research and development of medical preparations, medical products, and medical devices in the field of women’s health, reproductive health, and sexual health; Providing medical scientific research information in the fields of women’s health, reproductive health, and sexual health
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Drug delivery agents consisting of compounds that facilitate delivery of a wide range of pharmaceuticals; Drug delivery agents in the form of topical cream that facilitate the delivery of pharmaceutical preparations
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Pharmaceutical preparations for use in the field of women's health; intravaginal drug delivery device for the continuous release of pharmaceutical preparations, sold filled with hormones for supporting in-vitro fertilization and regulating pre-term birth; hormones; hormones for medical purposes
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Pharmaceutical preparations for use in the field of women's health; pharmaceutical preparations for treating dysmenorrhea, pelvic pain, sexual pain, and symptoms of endometriosis and menopause affecting sex; pharmaceutical preparations, namely, analgesic gels for vaginal use; pharmaceutical preparations, namely, selective estrogen receptor modulator suppositories for vaginal use; intravaginal drug delivery device for the continuous release of pharmaceutical preparations, sold filled with hormones; hormone replacement therapy preparations; hormones; vaginal preparations, namely, vaginal melatonin
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Pharmaceutical preparations for use in the field of women's health; Pharmaceutical preparations for treatment of female sexual arousal disorder, sexual pain, pelvic pain, dysmenorrhea, and symptoms of menopause and endometriosis affecting sex; Analgesic creams for vaginal and topical genital use; Creams for vaginal and topical genital use to increase blood flow through vasodilation
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Vaginal suppositories being pharmaceutical preparations for promoting healthy microbiome; vaginal preparations, namely, probiotic compositions in the form of vaginal suppositories
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Pharmaceutical preparations for use in the field of women's health; pharmaceutical preparations for the treatment of vaginal infections; anti-infectives
15.
COMPOSITIONS AND METHODS FOR TREATING VULVAR AND VAGINAL ATROPHY (VVA)
The present disclosure generally relates to compositions and techniques for treatment of vulvar and vaginal atrophy (VVA). In some embodiments, a composition comprising tamoxifen and/or pharmaceutically acceptable salts thereof. The composition may be applied intravaginally to a vagina of a subject. In addition, certain embodiments as described herein are generally directed to techniques for making or using such compositions, kits including such compositions, or the like.
The present disclosure generally relates to compositions and techniques for treatment of female sexual dysfunction (FSD), including female sexual arousal disorder (FSAD). In some embodiments, a composition such as a cream may be applied to the genital of a subject. The composition may also contain an active ingredient for treatment of FSD and/or FSAD, e.g., sildenafil, and/or pharmaceutically acceptable salts thereof. In addition, certain embodiments as described herein are generally directed to techniques for using such compositions, kits including such compositions, or the like.
A61K 31/519 - PyrimidinesPyrimidines hydrogénées, p. ex. triméthoprime condensées en ortho ou en péri avec des hétérocycles
A61K 31/4985 - Pyrazines ou pipérazines condensées en ortho ou en péri avec des systèmes hétérocycliques
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
A61K 31/506 - PyrimidinesPyrimidines hydrogénées, p. ex. triméthoprime non condensées et contenant d'autres hétérocycles
A61K 31/53 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec trois azote comme seuls hétéro-atomes d'un cycle, p. ex. chlorazanil, mélamine
A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur
A61P 15/00 - Médicaments pour le traitement des troubles génitaux ou sexuelsContraceptifs
A61P 15/02 - Médicaments pour le traitement des troubles génitaux ou sexuelsContraceptifs pour les pathologies du vagin
17.
COMPOSITIONS AND METHODS FOR TREATING DYSMENORRHEA
The present disclosure generally relates to compositions and techniques for treatment of dysmenorrhea using intravaginal delivery. In some embodiments, a composition such as a gel may be applied to the vagina of a subject that is relatively viscous, for example, with a viscosity at room temperature of at least 800,000 cP. The composition may also contain an active ingredient for treatment of dysmenorrhea (e.g., primary dysmenorrhea), e.g., diclofenac, and/or pharmaceutically acceptable salts thereof. In addition, certain embodiments as described herein are generally directed to techniques for making or using such compositions, kits including such compositions, or the like.
A61K 47/10 - AlcoolsPhénolsLeurs sels, p. ex. glycérolPolyéthylène glycols [PEG]PoloxamèresAlkyléthers de PEG/POE
A61K 47/12 - Acides carboxyliquesLeurs sels ou anhydrides
A61K 47/36 - PolysaccharidesLeurs dérivés, p. ex. gommes, amidon, alginate, dextrine, acide hyaluronique, chitosane, inuline, agar-agar ou pectine
A61F 5/50 - Dispositifs pour empêcher la succion des doigts
A61F 6/06 - Dispositifs de contraceptionPessairesDispositifs pour les introduire à usage féminin
A61F 6/14 - Dispositifs de contraceptionPessairesDispositifs pour les introduire à usage féminin du type intra-utérin
A61K 31/196 - Acides carboxyliques, p. ex. acide valproïque ayant un groupe amino le groupe amino étant lié directement à un cycle, p. ex. acide anthranilique, acide méfénamique, diclofénac, chlorambucil
A61K 31/5575 - Eicosanoïdes, p. ex. leucotriènes ayant un cycle cyclopentane, p. ex. prostaglandine E2, prostaglandine F2-alpha
A61M 31/00 - Dispositifs pour l'introduction ou la rétention d'agents, p. ex. de remèdes, dans les cavités du corps
A61P 15/00 - Médicaments pour le traitement des troubles génitaux ou sexuelsContraceptifs
A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p. ex. agents antirhumatismauxMédicaments anti-inflammatoires non stéroïdiens [AINS]
18.
COMPOSITIONS AND TECHNIQUES FOR TREATMENT OF POLYCYSTIC OVARIAN SYNDROME (PCOS) AND ENDOMETRIOSIS
The present disclosure generally relates to compositions and methods for treating polycystic ovarian syndrome (PCOS) and/or endometriosis. The composition may contain an active ingredient for treatment of PCOS and/or endometriosis, e.g., hydroxychloroquine, and/or salts thereof. In some embodiments, a composition such as a gel may be applied to the vagina of a subject that is relatively viscous, for example, with a viscosity at room temperature of at least 1.5 million cP. Compositions having such relatively high viscosities may be useful, for example, to prevent the composition from readily exiting the vagina or degrading too quickly. In some embodiments, a drug delivery device containing the active agent may be inserted in the vagina. In some embodiments, the drug delivery device is an intravaginal ring.
A61K 47/10 - AlcoolsPhénolsLeurs sels, p. ex. glycérolPolyéthylène glycols [PEG]PoloxamèresAlkyléthers de PEG/POE
A61K 47/12 - Acides carboxyliquesLeurs sels ou anhydrides
A61K 47/36 - PolysaccharidesLeurs dérivés, p. ex. gommes, amidon, alginate, dextrine, acide hyaluronique, chitosane, inuline, agar-agar ou pectine
A61F 6/06 - Dispositifs de contraceptionPessairesDispositifs pour les introduire à usage féminin
A61F 6/14 - Dispositifs de contraceptionPessairesDispositifs pour les introduire à usage féminin du type intra-utérin
A61K 31/196 - Acides carboxyliques, p. ex. acide valproïque ayant un groupe amino le groupe amino étant lié directement à un cycle, p. ex. acide anthranilique, acide méfénamique, diclofénac, chlorambucil
A61K 31/5575 - Eicosanoïdes, p. ex. leucotriènes ayant un cycle cyclopentane, p. ex. prostaglandine E2, prostaglandine F2-alpha
A61M 31/00 - Dispositifs pour l'introduction ou la rétention d'agents, p. ex. de remèdes, dans les cavités du corps
A61P 15/00 - Médicaments pour le traitement des troubles génitaux ou sexuelsContraceptifs
A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p. ex. agents antirhumatismauxMédicaments anti-inflammatoires non stéroïdiens [AINS]
Disclosed herein are intravaginal ring (IVR) devices comprising barriers that may be metal, polymeric or combinations of metal and polymeric. The IVRs are useful for contraception, treating and/or preventing sexually transmitted diseases, and treating and/or preventing bacterial infections. The IVR's are resistant to distortion due to absorption of vaginal fluids. This allows the IVRs to perform better over time as compared to other intravaginal rings made with copolymeric silicone.
The present disclosure generally relates to compositions and methods for treating polycystic ovarian syndrome (PCOS) and/or endometriosis. The composition may contain an active ingredient for treatment of PCOS and/or endometriosis, e.g., melatonin, a melatonin receptor agonist, and/or salts thereof. In some embodiments, a composition such as a gel may be applied to the vagina of a subject that is relatively viscous, for example, with a viscosity at room temperature of at least 1.5 million cP. Compositions having such relatively high viscosities may be useful, for example, to prevent the composition from readily exiting the vagina or degrading too quickly. In some embodiments, a drug delivery device containing the active agent may be inserted in the vagina. In some embodiments, the drug delivery device is an intravaginal ring.
A61K 31/196 - Acides carboxyliques, p. ex. acide valproïque ayant un groupe amino le groupe amino étant lié directement à un cycle, p. ex. acide anthranilique, acide méfénamique, diclofénac, chlorambucil
A61K 31/5575 - Eicosanoïdes, p. ex. leucotriènes ayant un cycle cyclopentane, p. ex. prostaglandine E2, prostaglandine F2-alpha
A61K 47/10 - AlcoolsPhénolsLeurs sels, p. ex. glycérolPolyéthylène glycols [PEG]PoloxamèresAlkyléthers de PEG/POE
A61K 47/12 - Acides carboxyliquesLeurs sels ou anhydrides
A61K 47/36 - PolysaccharidesLeurs dérivés, p. ex. gommes, amidon, alginate, dextrine, acide hyaluronique, chitosane, inuline, agar-agar ou pectine
A61M 31/00 - Dispositifs pour l'introduction ou la rétention d'agents, p. ex. de remèdes, dans les cavités du corps
A61P 15/00 - Médicaments pour le traitement des troubles génitaux ou sexuelsContraceptifs
A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p. ex. agents antirhumatismauxMédicaments anti-inflammatoires non stéroïdiens [AINS]
21.
METHODS AND DEVICES FOR HORMONE REPLACEMENT THERAPY
A drug delivery device for use in the treatment of one or more symptoms of menopause in a subject, comprising intravaginally inserting the implantable drug delivery device to the subject, wherein the implantable drug delivery device comprises an estrogen and a progestin, and further wherein the implantable drug delivery device provides a baseline-adjusted steady state plasma estrogen concentration between about 15 pg/mL and about 50 pg/mL in the subject.
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
A61K 31/565 - Composés contenant des systèmes cycliques du cyclopenta[a]hydrophénanthrèneLeurs dérivés, p. ex. stéroïdes non substitués en position 17 bêta par un atome de carbone, p. ex. œstrane, œstradiol
A61K 31/57 - Composés contenant des systèmes cycliques du cyclopenta[a]hydrophénanthrèneLeurs dérivés, p. ex. stéroïdes substitués en position 17 bêta par une chaîne à deux atomes de carbone, p. ex. prégnane ou progestérone
A61K 47/32 - Composés macromoléculaires obtenus par des réactions faisant intervenir uniquement des liaisons non saturées carbone-carbone, p. ex. carbomères
The present disclosure generally relates to compositions and techniques for vaginal insertion. In some embodiments, a composition such as a gel may be applied to the vagina of a subject that is relatively viscous, for example, with a viscosity at room temperature of at least 1.5 million cP. The composition may also contain an active ingredient, e.g., dinoprostone, diclofenac, and/or salts thereof. Compositions having such relatively high viscosities may be useful, for example, to prevent the composition from readily exiting the vagina or degrading too quickly. This may, for example, allow the composition to release the active ingredient over a relatively long period of time to the vagina. In some embodiments, such compositions may be prepared by removing air from the composition to increase its viscosity or cause the composition to form a gel, etc. In addition, certain embodiments as described herein are generally directed to techniques for making or using such compositions, kits including such compositions, or the like.
A61K 31/196 - Acides carboxyliques, p. ex. acide valproïque ayant un groupe amino le groupe amino étant lié directement à un cycle, p. ex. acide anthranilique, acide méfénamique, diclofénac, chlorambucil
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
A61K 31/5575 - Eicosanoïdes, p. ex. leucotriènes ayant un cycle cyclopentane, p. ex. prostaglandine E2, prostaglandine F2-alpha
A61K 47/10 - AlcoolsPhénolsLeurs sels, p. ex. glycérolPolyéthylène glycols [PEG]PoloxamèresAlkyléthers de PEG/POE
A61K 47/12 - Acides carboxyliquesLeurs sels ou anhydrides
A61K 47/34 - Composés macromoléculaires obtenus par des réactions autres que celles faisant intervenir uniquement des liaisons non saturées carbone-carbone, p. ex. polyesters, acides polyaminés, polysiloxanes, polyphosphazines, copolymères de polyalkylène glycol ou de poloxamères
A61K 47/36 - PolysaccharidesLeurs dérivés, p. ex. gommes, amidon, alginate, dextrine, acide hyaluronique, chitosane, inuline, agar-agar ou pectine
23.
SYSTEMS AND METHODS FOR TREATMENT OF BACTERIAL VAGINOSIS
A pharmaceutical composition for use in the treatment of bacterial vaginosis, wherein said composition comprises a poloxamer, a stabilization polymer, and an active ingredient for treating the bacterial vaginosis, preferably clindamycin, wherein said composition has a viscosity of at least 1.5 million mPa·s.
A61K 31/7056 - Composés ayant des radicaux saccharide et des hétérocycles ayant l'azote comme hétéro-atome d'un cycle, p. ex. nucléosides, nucléotides contenant des cycles à cinq chaînons avec l'azote comme hétéro-atome d'un cycle
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
A pharmaceutical composition for use in the treatment of bacterial vaginosis, wherein said composition comprises a poloxamer, a stabilization polymer, and an active ingredient for treating the bacterial vaginosis, preferably clindamycin, wherein said composition has a viscosity of at least 1.5 million mPa.s.
A61K 31/7056 - Composés ayant des radicaux saccharide et des hétérocycles ayant l'azote comme hétéro-atome d'un cycle, p. ex. nucléosides, nucléotides contenant des cycles à cinq chaînons avec l'azote comme hétéro-atome d'un cycle
A61P 15/02 - Médicaments pour le traitement des troubles génitaux ou sexuelsContraceptifs pour les pathologies du vagin
A composition, comprising a poloxamer, a stabilization polymer, and diclofenac as an active ingredient suitable for treating dysmenorrhea, wherein the composition has a viscosity at room temperature of at least 1.5 million cP.
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
A61K 47/10 - AlcoolsPhénolsLeurs sels, p. ex. glycérolPolyéthylène glycols [PEG]PoloxamèresAlkyléthers de PEG/POE
A61K 31/196 - Acides carboxyliques, p. ex. acide valproïque ayant un groupe amino le groupe amino étant lié directement à un cycle, p. ex. acide anthranilique, acide méfénamique, diclofénac, chlorambucil
A61K 31/5575 - Eicosanoïdes, p. ex. leucotriènes ayant un cycle cyclopentane, p. ex. prostaglandine E2, prostaglandine F2-alpha
A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p. ex. agents antirhumatismauxMédicaments anti-inflammatoires non stéroïdiens [AINS]
A61P 15/00 - Médicaments pour le traitement des troubles génitaux ou sexuelsContraceptifs
Disclosed herein are intravaginal ring (IVR) devices comprising barriers that may be metal, polymeric or combinations of metal and polymeric. The IVRs are useful for contraception, treating and/or preventing sexually transmitted diseases, and treating and/or preventing bacterial infections. The IVR's are resistant to distortion due to absorption of vaginal fluids. This allows the IVRs to perform better over time as compared to other intravaginal rings made with copolymeric silicone.
Disclosed herein are intravaginal ring (IVR) devices comprising barriers that may be metal, polymeric or combinations of metal and polymeric. The IVRs are useful for contraception, treating and/or preventing sexually transmitted diseases, and treating and/or preventing bacterial infections. The IVR's are resistant to distortion due to absorption of vaginal fluids. This allows the IVRs to perform better over time as compared to other intravaginal rings made with copolymeric silicone.
Disclosed herein are intravaginal ring devices that are resistant to distortion due to absorption of vaginal fluids. This allows the rings to perform better over time as compared to other intravaginal rings made with copolymeric silicone.
05 - Produits pharmaceutiques, vétérinaires et hygièniques
10 - Appareils et instruments médicaux
Produits et services
Contraceptive preparations Medical products, namely, a polymer intra-vaginal ring with an incorporated mesh insert that is designed to reside in the vaginal fornix, essentially covering the external orifice of the cervix, and medical devices and contraceptive apparatuses for vaginal and intrauterine contraception
